Epizyme shares slump as can­cer drug da­ta up­date dis­ap­points

An­a­lysts hate to be dis­ap­point­ed, and that’s just what Epizyme $EPZM ac­com­plished this morn­ing as it up­dat­ed its camp fol­low­ers with the lat­est da­ta on tazeme­to­stat for dif­fuse large B-cell lym­phoma.

Ini­tial­ly, ob­servers had been pleased by the 40% over­all re­sponse rate that re­searchers had been track­ing on DL­B­CL for its EZH2 in­hibitor. Then this morn­ing the com­pa­ny pro­vid­ed an up­date on their Phase II with more pa­tients in the mix, and the ORR dropped to 29%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER